Andreas Argyrides
Stock Analyst at Oppenheimer
(4.45)
# 280
Out of 4,873 analysts
111
Total ratings
48.89%
Success rate
22.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALA KALA BIO | Assumes: Outperform | $15 | $4.70 | +219.15% | 1 | Jun 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $31.57 | +93.22% | 1 | Jun 2, 2025 | |
| AQST Aquestive Therapeutics | Assumes: Outperform | $15 → $7 | $3.25 | +115.38% | 5 | Jun 2, 2025 | |
| ABEO Abeona Therapeutics | Assumes: Outperform | $19 | $5.98 | +217.73% | 1 | Jun 2, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $60 → $34 | $10.42 | +226.30% | 1 | Jun 2, 2025 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $3 | $0.84 | +257.14% | 2 | May 29, 2025 | |
| LQDA Liquidia | Downgrades: Underperform | $13 | $13.60 | -4.41% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.51 | +690.51% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $12.00 | +650.00% | 1 | May 13, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $15 → $9 | $2.16 | +316.67% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $13.65 | +9.89% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $173.00 | +4.62% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $13.15 | +166.26% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $3.25 | +700.00% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $8.01 | -12.61% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $47.37 | +119.55% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.84 | +495.24% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.36 | +561.76% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $17.26 | +10.08% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.44 | +49.22% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $8.55 | +145.61% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $17.46 | +1,182.93% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.90 | +138.49% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.79 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.70 | +898.15% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.85 | +159.74% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.58 | +1,618.21% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $54.14 | +29.29% | 6 | Aug 1, 2023 |
KALA BIO
Jun 2, 2025
Assumes: Outperform
Price Target: $15
Current: $4.70
Upside: +219.15%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $31.57
Upside: +93.22%
Aquestive Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $3.25
Upside: +115.38%
Abeona Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $19
Current: $5.98
Upside: +217.73%
Dyne Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $60 → $34
Current: $10.42
Upside: +226.30%
InflaRx
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.84
Upside: +257.14%
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $13.60
Upside: -4.41%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.51
Upside: +690.51%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $12.00
Upside: +650.00%
ProQR Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.16
Upside: +316.67%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.65
Upside: +9.89%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $173.00
Upside: +4.62%
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $13.15
Upside: +166.26%
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.25
Upside: +700.00%
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $8.01
Upside: -12.61%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $47.37
Upside: +119.55%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.84
Upside: +495.24%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.36
Upside: +561.76%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $17.26
Upside: +10.08%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.44
Upside: +49.22%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $8.55
Upside: +145.61%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $17.46
Upside: +1,182.93%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.90
Upside: +138.49%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.79
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.70
Upside: +898.15%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $3.85
Upside: +159.74%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.58
Upside: +1,618.21%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $54.14
Upside: +29.29%